[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"major-depression-severe\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:major-depression-severe":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,55,80,113,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100650371","eeg-microstate-parameters-and-neuroinflammatory-biomarkers-in-patients-with-treatment-resistant-major-depressive-disorder-receiving-ect-100650371",false,"NCT07748091","EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT","The Relationship of EEG Microstate Parameters and Neuroinflammatory Biomarkers With Treatment Response in Patients With Treatment-Resistant Major Depressive Disorder Receiving Electroconvulsive Therapy","Inclusion Criteria:\n\nPatient Group\n\n* Age 18-60 years\n* Diagnosis of Major Depressive Disorder, current major depressive episode, according to DSM-5 criteria.\n* Clinical indication for electroconvulsive therapy (ECT).\n* Ability to provide written informed consent.\n* Willingness to participate in the study.\n\nHealthy Control Group:\n\n* Age ≥55 years.\n* No current psychiatric disorder.\n* No known neurological disorder.\n* Good general physical health.\n* No current use of medications known to affect EEG activity or inflammatory biomarkers significantly.\n* Ability to provide written informed consent.\n* Willingness to participate in the study.\n\nExclusion Criteria:\n\n* Primary neurological disorders (e.g., dementia or traumatic brain injury).\n* Schizophrenia or other psychotic disorders.\n* Bipolar disorder diagnosis,\n* Intracranial space-occupying lesions.\n* Increased intracranial pressure.\n* Myocardial infarction within the previous 3 months.\n* Cerebrovascular disease within the previous month.\n* Unstable cerebral aneurysm.\n* Pheochromocytoma.\n* Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within the previous month.\n* Cognitive impairment severe enough to prevent adequate cooperation during EEG recording.\n* Current alcohol or substance use disorder.\n* Active infectious disease.\n* Autoimmune or chronic inflammatory disorders.\n* Current use of systemic corticosteroids, immunosuppressive agents, or other medications known to affect inflammatory biomarkers significantly.",true,"ALL","18 Years","60 Years",{"count":21,"type":22},62,"ESTIMATED","2 Months","OBSERVATIONAL","This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in patients diagnosed with Major Depressive Disorder who are resistant to at least two antidepressant treatments, using microstate analysis derived from resting-state electroencephalography (EEG) recordings. Within this scope, EEG recordings obtained before and after ECT will be compared to determine the relationships between changes in microstate parameters and inflammatory marker levels, clinical variables, and psychometric scale scores reflecting clinical improvement.\n\nPeripheral blood samples collected from the same patient group will be analyzed for complete blood count parameters as well as levels of interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), soluble glycoprotein 130 (sgp-130), soluble interleukin-6 receptor (sIL-6R), interferon gamma-induced protein 10 kDa (IP-10), and C-reactive protein (CRP). In addition, inflammatory indices, including the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR), will be calculated. The association between baseline levels of these biomarkers and treatment response will be evaluated. Moreover, changes in biomarker levels following ECT will be statistically examined in relation to clinical scale scores and EEG microstate parameters.\n\nAlthough microstate analysis and inflammatory biomarkers have each been extensively investigated in psychiatric disorders, studies evaluating these two biomarkers together, particularly with the inclusion of healthy control participants, remain limited. In this regard, the present study aims to evaluate the effects of ECT on patients with treatment-resistant depression using objective neurophysiological indicators, to contribute to the understanding of the pathophysiology of depression at the level of brain networks, and to provide a scientific basis for the development of personalized treatment approaches in the future.",[27,28,29,30,31,32,33,34],"Major Depression Moderate","Major Depression Severe","Major Depression With Comorbid Anxiety Symptoms","Major Depression With Panic Attacks","Major Depression With Psychotic Features","Major Depressive Episode","Major Depressive Disorder (MDD","Major Depression",[36,37,38,39,40,41,34,32],"ECT","EEG","Treatment Resistant Depression","Difficult to Treat Depression","Microstate","Inflammatory biomarker","RECRUITING","2026-07-31",{"date":45,"type":46},"2026-08-05","ACTUAL",{"date":48,"type":46},"2026-01-01",{"date":50,"type":22},"2027-03",{"name":52,"class":53},"Istanbul University - Cerrahpasa","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":16,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":64,"conditions":65,"keywords":71,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":54},"100649721","eeg-microstate-and-neuroinflammatory-biomarkers-in-older-age-patients-with-major-depressive-disorder-receiving-ect-100649721","NCT07740694","EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT","The Relationship Between EEG Microstate Parameters, Neuroinflammatory Biomarkers and Treatment Response in Older Patients With Major Depressive Disorder or Bipolar Disorder Undergoing Electroconvulsive Therapy","Inclusion Criteria:\n\nPatient Group\n\n* Age ≥55 years.\n* Diagnosis of Major Depressive Disorder or Bipolar Disorder, current major depressive episode, according to DSM-5 criteria.\n* Clinical indication for electroconvulsive therapy (ECT).\n* Ability to provide written informed consent.\n* Willingness to participate in the study.\n\nHealthy Control Group:\n\n* Age ≥55 years.\n* No current psychiatric disorder.\n* No known neurological disorder.\n* Good general physical health.\n* No current use of medications known to affect EEG activity or inflammatory biomarkers significantly.\n* Ability to provide written informed consent.\n* Willingness to participate in the study.\n\nExclusion Criteria:\n\n* Primary neurological disorders (e.g., dementia or traumatic brain injury).\n* Schizophrenia or other psychotic disorders.\n* Intracranial space-occupying lesions.\n* Increased intracranial pressure.\n* Myocardial infarction within the previous 3 months.\n* Cerebrovascular disease within the previous month.\n* Unstable cerebral aneurysm.\n* Pheochromocytoma.\n* Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within the previous month.\n* Cognitive impairment severe enough to prevent adequate cooperation during EEG recording.\n* Current alcohol or substance use disorder.\n* Active infectious disease.\n* Uncontrolled autoimmune or chronic inflammatory disorders. Participants with stable disease who had received the same maintenance treatment within the previous 3 months were eligible for inclusion.","55 Years",{"count":21,"type":22},"This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in older age patients diagnosed with Major Depressive Episode, Major Depression, and Bipolar Disorder, using microstate analysis derived from resting-state electroencephalography (EEG) recordings. Within this scope, EEG recordings obtained before and after ECT will be compared to determine the relationships between changes in microstate parameters and inflammatory marker levels, clinical variables, and psychometric scale scores reflecting clinical improvement. Peripheral blood samples collected from the same patient group will be analyzed for complete blood count parameters as well as levels of interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), soluble glycoprotein 130 (sgp-130), soluble interleukin-6 receptor (sIL-6R), interferon gamma-induced protein 10 kDa (IP-10), and C-reactive protein (CRP). In addition, inflammatory indices, including the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR), will be calculated. The association between baseline levels of these biomarkers and treatment response will be evaluated. Moreover, changes in biomarker levels following ECT will be statistically examined in relation to clinical scale scores and EEG microstate parameters. Although microstate analysis and inflammatory biomarkers have each been extensively investigated in psychiatric disorders, studies evaluating these two biomarkers together, particularly with the inclusion of healthy control participants, in the older age population remain limited. In this regard, the present study aims to evaluate the effects of ECT on older age patients using objective neurophysiological indicators, contribute to the understanding of the pathophysiology of depression at the level of brain networks, and provide a scientific basis for the development of personalised treatment approaches in the future.",[27,28,29,30,31,32,66,67,68,69,70],"Bipolar Affective Disorder","Bipolar Depression Depressed Phase","Bipolar Depression","Bipolar Anhedonic Depression","Catatonia",[36,32,34,41,37,40,38,39,68,72],"Bipolar Disorder","2026-07-28",{"date":43,"type":46},{"date":76,"type":46},"2025-12-01",{"date":78,"type":22},"2027-02",{"name":52,"class":53},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":54},"100631616","phase-1-shortened-lsd-intervention-for-major-depressive-disorder-100631616","NCT07503002","Shortened LSD Intervention for Major Depressive Disorder","SLIM","Inclusion Criteria:\n\n* Have given written informed consent\n* Meet DSM-5 criteria for MDD\n* MADRS \\>= 28 at screening Can read, write, and speak English fluently\n* Be judged by study team clinicians to be at low risk for suicidality\n\nExclusion Criteria:\n\n* Women who are pregnant, nursing, or not practicing an effective means of birth control\n* Cardiovascular conditions: hypertension with resting blood pressure systolic \\>139 or diastolic \\>89, angina, heart rate \\> 99, a clinically significant ECG abnormality (e.g., atrial fibrillation, QTc \\> 450), TIA in the last 6 months stroke, peripheral or pulmonary vascular disease, cardiac valvulopathy\n* Epilepsy\n* Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia\n* Currently taking antipsychotics, or MAO inhibitors\n* Patients taking antidepressant medications and unable to taper\n* Moderate or strong CYP2D6 inhibitor antidepressants must undergo a washout period of 4 weeks or five half-lives prior to treatment\n* Currently taking CYP2D6 inhibitor other than an antidepressant that will be tapered\n* Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or UGT1A9 inhibitors or UGT1A10 inhibitors such as phenytoin, regorafenib, eltrombopag\n* Have a seizure disorder, multiple sclerosis, history of significant head trauma, CNS tumor, movement disorders or any neurodegenerative condition\n* Morbidly obese (\\>100 lbs. above ideal body weight, or BMI \\>=40, or BMI \\>=35 with high blood pressure or diabetes)\n* Be judged by a study team clinician to be at risk for moderate or severe alcohol or benzodiazepine withdrawal\n* Body weight \\\u003C 45 kg\n* Significant acute adverse reaction (e.g., dystonia) to an antipsychotic\n* Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (including substance-induced), Bipolar I or II Disorder or Major\n* Depression with psychotic features\n* Have a first degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or Bipolar I Disorder.","21 Years","70 Years",{"count":90,"type":22},10,"INTERVENTIONAL",[93],"PHASE1","The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.",[27,28,34],[97,98,99,100,101,102],"LSD","lysergic acid diethylamide","depression","MDD","major depression","major depressive","NOT_YET_RECRUITING","2026-07-23",{"date":106,"type":46},"2026-07-24",{"date":108,"type":22},"2026-08-31",{"date":110,"type":22},"2027-12-01",{"name":112,"class":53},"Johns Hopkins University",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":91,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100646890","phase-1-oral-and-sublingual-ketamine-100646890","NCT07683988","Oral and Sublingual Ketamine","A Comparative Analysis of the Pharmacokinetics of Oral and Sublingual Ketamine as Adjunctive Therapies in Major Depressive Disorder","Inclusion Criteria:\n\n* Participants must meet all the following criteria to be eligible for the study. Appendix B is a checklist that will be used by Dr. Hammound for screening, based on the following inclusion and exclusion criteria.\n\n  1. Age: Between 18 and 65 years (inclusive) at the time of screening.\n  2. Weight: Equal to or greater than 50 kg (110 lbs).\n  3. Diagnosis: A current diagnosis of Major Depressive Disorder (MDD), moderate to severe in intensity, as defined by the DSM-5 criteria.\n  4. Current Episode: Experiencing a moderate to severe Major Depressive Episode (MDE) at screening.\n  5. Ongoing Treatment: Actively receiving pharmacological treatment for MDD at the time of enrollment.\n  6. Treatment Resistance: Documented history of inadequate response to at least two antidepressant medications, each from a different pharmacological class, administered at an adequate dose and duration.\n  7. Capacity and Consent: Able and willing to provide written informed consent after understanding the nature, risks, and potential benefits of the study.\n  8. Clinical Oversight: Currently under the regular care of a psychiatrist or general practitioner (GP).\n  9. Support System: Has a responsible adult (e.g., family member or caregiver) who can accompany them from study visits or ensure safe transportation after ketamine has been used.\n  10. Able to speak, read and understand English\n\nExclusion Criteria:\n\n* Participants will be excluded if any of the following criteria apply:\n\n  1. Suicidality: Active suicidal ideation with plan or intent, or suicidal behavior, within the past 3 months.\n  2. Concomitant Medications: Use of medications that may pose a risk of respiratory depression or serious adverse events when combined with ketamine (e.g., benzodiazepines, opioids, barbiturates).\n  3. Medical Comorbidities: Presence or history of significant or unstable medical conditions that could interfere with study participation or pose a safety risk, including but not limited to cerebrovascular accident, cardiac decompensation, large vessel aneurysms, glaucoma etc.. Participants with clinically significant laboratory abnormalities, as determined by the investigator, will also be excluded.\n  4. Hypersensitvity to ketamine\n  5. Uncontrolled hypertension (blood pressure ≥140\u002F90 mmHg at screening, which may be repeated after 30 minutes rest)\n  6. Psychiatric Comorbidities: Diagnosis of bipolar disorder, psychotic disorders, or history of psychotic symptoms.\n  7. Substance Use: Clinically significant alcohol or substance use disorder within the last 6 months, as defined by DSM-5 criteria.\n  8. Cognitive Impairment: Any condition resulting in impaired capacity to understand or consent to participation or to comply with study procedures.\n  9. Pregnancy and Lactation: Pregnant or breastfeeding individuals.\n  10. Concurrent Research Participation: Participation in another interventional clinical trial or use of an investigational drug within the 30 days prior to screening.\n  11. Current or recent (within 90 days) treatment with ketamine (oral, IV or intranasal).\n  12. ECG demonstrates abnormalities like Qtc interval\\>470 ms or any arrhythmia reported as clinically significant or abnormal by the interpreting physician. Exclusionary findings would include uncontrolled atrial fibrillation, ventricular arrhythmias, heart block, or other abnormalities that could pose a safety risk with ketamine administration","65 Years",{"count":90,"type":22},[93],"Major Depressive Disorder (MDD) is one of the most common and severe mental illnesses in the world. Ketamine treatment, especially intravenous ketamine (IVK) and intranasal esketamine (INE), is becoming more popular and is being used more. But these ways of administering aren't perfect. They mostly have problems with cost, accessibility, and the issues of administering. The oral and sublingual routes of ketamine are cheaper alternatives, but they haven't been looked into as much in the medical and academic circles. This is a small pilot feasibility study, involving ten patient participants who will be randomly assigned to take ketamine by oral and sublingual routes as part of a single-blind, crossover design. A local London pharmacy-Ultimate Care Compounding will provide the ketamine formulations.\n\nTen patients between 18 and 65 years old with Major Depressive Disorder will be recruited from the Mental Health Care Programs at LHSC, Victoria Hospital and SJHC, Parkwood Institute, (that has treatment resistant depression treatment focus). After a screening baseline visit, which will include clinical interviews with medication reconciliation, psychiatric evaluations, routine standard laboratory tests, and an electrocardiogram (ECG).\n\nDue to capacity limitations at the Centre for Clinical Investigation and Therapeutics (CCIT), a maximum of 5 participants will undergo pharmacokinetic sampling simultaneously, enrolment will proceed in two sequential groups with treatment order assigned by group. Group A (n=5): The first 5 eligible participants will receive oral ketamine in Treatment Period 1 and sublingual ketamine in Treatment Period 2. Group B (n=5): The next 5 eligible participants will receive sublingual ketamine in Treatment Period 1 and oral ketamine in Treatment Period 2. Recruitment for Group B will commence once Group A has completed the clinical intervention phase.\n\nDuring Monday and Thursday of each of Weeks 1 and 2, Group A will receive oral ketamine, while Group B will receive sublingual ketamine. Weeks 3 and 4 are a washout period. In Weeks 5 and 6, on Mondays and Thursdays, groups will switch to the other form of administration \\[See flowchart of study procedure\\]. Weeks 7 and 8 are washout periods to ensure consistency with the first half of the study and provide a similar framework for clinical assessments. Blood samples will be collected at 2 time points at the Center for Clinical Investigation and Therapeutics at University Hospital. The study goal is to help define safe and effective oral\u002FSL ketamine doses based on Pharmacokinetic profiles.",[28],[126,127],"ketamine","Depression","2026-06-28",{"date":130,"type":46},"2026-07-06",{"date":132,"type":22},"2026-10-01",{"date":134,"type":22},"2027-10-01",{"name":136,"class":53},"Western University, Canada",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":91,"phases":147,"briefSummary":149,"conditions":150,"keywords":159,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":54},"100573643","ketogenic-metabolic-therapy-in-schizophrenia-bipolar-disorder-major-depressive-disorder-deep-omic-profiling-100573643","NCT06748950","Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling","A Randomized Controlled Trial of a Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling","Inclusion Criteria:\n\n1. diagnosed with bipolar disorder (BD), major depressive disorder (MDD), and or schizophrenia\n\n   1. For individuals diagnosed with bipolar disorder (BD):\n\n      * Meet DSM V criteria for BD (any subtype)\n      * Not mild\n      * \\>40 on BPRS\n      * clinically stable (with no hospitalization for past 3 months)\n   2. For individuals diagnosed with major depressive disorder (MDD):\n\n      * Not mild\n      * PHQ-9 \\> 10\n      * clinically stable (with no hospitalization for past 3 months)\n   3. For individuals diagnosed with schizophrenia:\n\n      * Meet DSM V criteria for schizophrenia (any subtype)\n      * Not mild\n      * \\>40 on BPRS\n      * clinically stable (with no hospitalization for past 3 months)\n2. Participants may currently be on a stable and adequate dose of SSRI antidepressant therapy or other psychiatric medication. Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, or trazodone) will be allowed if the therapy has been stable for at least four weeks prior to screening and if it is expected to remain stable. Participants may be switched from other classes of medication to another medication class by their psychiatrist or primary care doctor, but need to be stable enough to enroll and adhere to study procedures.\n3. willing and able to give informed consent for participation in English.\n4. live within the United States.\n\n   \\--------------------------------------------------------------------------------\n\nExclusion Criteria:\n\n1. has started the ketogenic diet or was in ketosis within 3 months of wanting to enroll\n2. pregnant or nursing\n3. insulin dependent\n4. comorbidity of developmental delay\n5. in a current severe mood or psychotic state when entering the study that would prohibit compliance with study visits or dietary programs.\n6. any one who has been hospitalized or taken clozapine at doses above 550mg over the past 3 months\n7. inability to complete baseline measurements\n8. severe renal or hepatic insufficiency\n9. cardiovascular dysfunction, including diagnosis of:\n\n   * Congestive heart failure\n   * Angina\n   * Arrhythmias\n   * Cardiomyopathy\n   * Valvular heart disease\n10. active substance abuse with illicit drugs or alcohol and\u002For current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by DSM-IV-TR), with the exception of nicotine or cannabis dependence\n11. active suicidal and considered at significant risk for suicide during course of study\n12. participation in any clinical trial- within the past month or concurrent to study participation- with an investigational drug\u002Fdevice and\u002For intervention that may interfere with study participation\u002Fevaluation of results\n13. mild BPRS at screening or baseline visits\n14. history of TBI\n15. any other medical condition that may make diet intervention dangerous as determined by the study medical team (e.g. anorexia nervosa) or assessed by study team to have insufficient control over their food intake to adhere to study diets.\n16. any medical condition that physicians or the PI believe would interfere with study participation or evaluation of results\n17. history of familial hypercholesterolemia","80 Years",{"count":146,"type":22},120,[148],"NA","The goal of this randomized clinical trial is to be adequately powered to evaluate the effect of ketogenic metabolic therapy on the quality of life in serious mental illness, schizophrenia, bipolar disorder, major depressive disorder.",[151,152,72,153,154,28,155,156,157,158],"Schizophrenia","Schizophrenia and Related Disorders","Bipolar and Related Disorders","Major Depressive Disorder","Ketogenic Dieting","Ketosis","Metabolic Disease","Metabolic Syndrome",[160,161,162,163],"Mental Illness","Multiomics","Multi-omics","Omics Profiling","2025-05-13",{"date":166,"type":46},"2025-05-16",{"date":168,"type":22},"2025-07",{"date":170,"type":22},"2028-07",{"name":172,"class":53},"Stanford University"]